Panel Discussion: Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact
3:10 pm - Wednesday 7th October 2026
- How to determine when a biomarker‑enabled strategy truly advances the program, balancing scientific risk, portfolio focus, and capital efficiency?
- What can biotech do to evaluate partnership models that foster innovation while ensuring operational feasibility, sustainable costs, and long-term scalability of CDx?
- When to integrate biomarker considerations into early clinical development without overburdening trial design, patient recruitment, or organizational capacity?
